Dong Kim, MD, discusses the evolving decision-making process for selecting a frontline chemotherapy regimen in pancreatic cancer.
Dong Kim, MD
Advertisement
Dong Kim, MD, is an oncologist and hematologist at Maryland Oncology Hematology.
Articles by Dong Kim, MD
Advertisement
Latest Updated Articles
Advertisement
Advertisement
Trending on OncLive
1
FDA Approves Sacituzumab Govitecan Monotherapy and In Combination With Pembrolizumab in Frontline TNBC
2
FDA Approves Palbociclib Plus Trastuzumab, With/Without Pertuzumab, and ET as Maintenance in HR+, HER2+ Metastatic Breast Cancer
3
Iza-Bren Is Approved in China for Recurrent/Metastatic Nasopharyngeal Carcinoma
4
Dr Tolaney on the FDA Approval of First-Line Sacituzumab Govitecan Plus Pembrolizumab for TNBC
5